RHUMBLINE ADVISERS

Position in AMLX — Amylyx Pharmaceuticals, Inc.

CIK 1115418 BOSTON, MA

Position in AMLX

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$1,507,691

+$308,462 QoQ

Shares Held

108,467

+9.3% QoQ

Ownership

0.098%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2022

13 quarters on record

Voting authority Sole 20% Shared 0% None 80%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $438,094,582 across 50 Drug Manufacturers - Specialty & Generic names. AMLX ranks #24 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ZTS	Zoetis Inc.	1,229,009	$145,281,153
2	UTHR	UNITED THERAPEUTICS Corp	122,486	$72,631,748
3	NBIX	Neurocrine Biosciences Inc	303,820	$40,025,246
4	ELAN	Elanco Animal Health Inc	1,268,203	$30,348,097
5	VTRS	Viatris Inc	1,941,082	$26,224,017
6	ALKS	Alkermes plc.	449,531	$15,895,416
7	LNTH	Lantheus Holdings, Inc.	194,563	$14,757,603
8	HIMS	Hims & Hers Health, Inc.	643,856	$13,366,450

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,507,691	108,467	+9.3%	Shares	Sole	2026-05-12
2025-12-31	$1,199,229	99,274	+0.6%	Shares	Sole	2026-02-13
2025-09-30	$1,340,748	98,657	-1.9%	Shares	Sole	2025-11-06
2025-06-30	$644,692	100,576	+249.5%	Shares	Sole	2025-08-12
2024-06-30	$54,680	28,779	-58.5%	Shares	Sole	2024-08-01
2024-03-31	$197,104	69,403	+1.6%	Shares	Sole	2024-05-09
2023-12-31	$1,005,125	68,283	-1.0%	Shares	Sole	2024-02-08
2023-09-30	$1,262,657	68,960	+1.3%	Shares	Sole	2023-11-09
2023-06-30	$1,468,809	68,095	-10.4%	Shares	Sole	2023-08-08
2023-03-31	$2,228,725	75,962	+6.1%	Shares	Sole	2023-05-11
2022-12-31	$2,644,289	71,564	+56.3%	Shares	Sole	2023-02-14
2022-09-30	$1,289,072	45,793	+183.1%	Shares	Sole	2022-11-10
2022-06-30	$311,511	16,174	—	Shares	Sole	2022-08-11
No filing history on record for this holder in this stock.